BeOne Medicines: Neoplasms trials

The registry lists 17 Neoplasms studies with BeOne Medicines as lead sponsor. 2 are open to participants now and 10 have results posted.

Phase 1 16Phase 2 6(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study of Sonrotoclax (BGB-11417) in Children With Relapsed or Refractory Acute Myeloid Leukemia and B-cell Acute Lymphoblastic LeukemiaNot yet recruitingNCT07770698Phase 1/2
• A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell MalignanciesRecruitingNCT06634589Phase 1/2
• Treatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma With Ociperlimab (BGB-A1217) in Combination With Tislelizumab (BGB-A317) or RituximabCompletedNCT05267054Phase 1/2Results posted
• Efficacy and Safety of Tislelizumab in Combination With Fruquintinib in Participants With Selected Solid TumorsCompletedNCT04716634Phase 2Results posted
• Interaction Study of Zanubrutinib With Moderate and Strong CYP3A Inhibitors in Participants With B-Cell MalignanciesCompletedNCT04551963Phase 1Results posted
• A Phase 1b Study to Assess Sitravatinib in Combination With Tislelizumab in Participants With Advanced Solid TumorsCompletedNCT03666143Phase 1Results posted
• Study of BGB-A333 Alone and in Combination With Tislelizumab in Advanced Solid TumorsTerminatedNCT03379259Phase 1/2Results posted
• Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Participants With Locally Advanced or Metastatic Solid TumorsCompletedNCT03150810Phase 1Results posted
• Zanubrutinib (BGB-3111) in Combination With Tislelizumab (BGB-A317) in Participants With B-cell MalignanciesCompletedNCT02795182Phase 1Results posted
• The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Participants With Advanced Solid TumorsCompletedNCT02660034Phase 1Results posted
• BGB 3111 in Combination With Obinutuzumab in Participants With B-Cell Lymphoid MalignanciesCompletedNCT02569476Phase 1Results posted
• Study of the Safety and Pharmacokinetics of BGB-3111 in Subjects With B-Cell Lymphoid MalignanciesCompletedNCT02343120Phase 1/2Results posted
• Safety, Pharmacokinetics and Antitumor Activity of BGB-B167 Alone and in Combination With Tislelizumab in Participants With Solid Tumors in Chinese ParticipantsWithdrawnNCT05644626Phase 1
• Safety, Pharmacokinetics, and Antitumor Activity of BGB-B167 Alone and in Combination With Tislelizumab (BGB-A317) in Participants With Advanced Solid TumorsTerminatedNCT05494762Phase 1
• The Study of BGB-283 in Chinese Subjects With Local Advanced or Metastatic Malignant Solid TumorCompletedNCT03641586Phase 1
• Study of the Safety and Pharmacokinetics of BGB-283 in Patients With Solid TumorsCompletedNCT02610361Phase 1
• Phase 1a/1b BGB-290 for Advanced Solid Tumors.CompletedNCT02361723Phase 1